Lacerda, Lydia <br/><br/>
Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway.  [electronic resource] 

 -  Cardiovascular research  Nov 2009 
 - 201-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1755-3245 
<br/><br/><label>Standard No.: </label>10.1093/cvr/cvp274  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Androstadienes--pharmacology<br/>Animals<br/>Disease Models, Animal<br/>Extracellular Signal-Regulated MAP Kinases--antagonists & inhibitors<br/>Flavonoids--pharmacology<br/>Glycogen Synthase Kinase 3--metabolism<br/>Glycogen Synthase Kinase 3 beta<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Myocardial Infarction--metabolism<br/>Myocardial Reperfusion Injury--metabolism<br/>Myocardium--metabolism<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Phosphorylation<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Receptors, Tumor Necrosis Factor, Type I--genetics<br/>Receptors, Tumor Necrosis Factor, Type II--deficiency<br/>STAT3 Transcription Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Tumor Necrosis Factor-alpha--deficiency<br/>Tyrphostins--pharmacology<br/>Wortmannin